Lyndra Therapeutics, a spin-off from MIT's Robert Langer's lab in 2015, raised $101 million in its 2023 Series E funding and achieved positive results in a Phase 3 trial for its once-weekly oral risperidone (LYN-005). However, it failed to secure funding for additional safety studies, leading to the termination of the business and a complete layoff of its 60 employees on March 2025. During this bankruptcy process, Innoviva (INVA) acquired the LYNX platform, a gastric retention drug delivery system, for $10.2 million, with potential for up to $20 million in milestone payments and royalties on the first approved product. This highly discounted deal compared to the Series E valuation demonstrates Innoviva's opportunistic M&A strategy.

The LYNX platform is a technology that places a structure that unfolds in the stomach inside a standard-sized capsule, releasing drugs at a programmed rate for up to one month. It has undergone more than 600 human administrations in over 270 subjects and over 1,300 animal administrations, and is protected by over 50 registered patents. The STARLYNG-1 Phase 3 trial demonstrated that once-weekly risperidone (LYN-005) at 15mg and 45mg met the pharmacokinetic (PK) equivalence (90% CI) for Cmin, Cmax, and Cavg compared to daily Risperdal, and achieved the pre-specified success criteria with the maintenance of PANSS scores, leading to early termination. This represents a significant clinical data package acquired for $10.2 million.

Austin Hackett, MD, has been appointed CEO of Nortiva Bio, and the advisory board includes Langer, co-founder of Moderna and the original developer of the LYNX technology, Janet Woodcock, former acting director of the FDA, Giovanni Traverso of MIT/BWH, Kallyope CEO Jay Galeota, and Sophie Kornowski, former head of global partnering at Roche. This composition, encompassing academia, regulation, and business development, will serve as a strong asset in designing FDA regulatory pathways and negotiating partnerships with large pharmaceutical companies. Innoviva CEO Pavel Raifeld has outlined a strategy of pursuing both internal development and co-development opportunities.

The global controlled-release drug delivery market is projected to grow from $66.9 billion in 2025 to $115.3 billion in 2031 (CAGR of 9.49%), and the gastric retention drug delivery system market is expected to reach $2.01 billion in 2030. Competitors include Rani Therapeutics (RANI) with its RaniPill for oral delivery of biologics, and GSK's bioadhesive gastric retention technology. However, LYNX is the only platform that combines a modular design optimized for small-molecule APIs with Phase 3-level clinical data. A key differentiator is its potential to improve patient compliance compared to existing long-acting injectable (LAI) formulations.

The lead program for Nortiva is a once-monthly oral contraceptive, supported by a $5 million grant from the Bill & Melinda Gates Foundation, and has completed preclinical proof-of-concept (POC) studies. It targets the unmet need of approximately 50% of women who miss at least one dose per month. Leveraging the positive Phase 3 data for schizophrenia (LYN-005), the company plans to expand the platform into other chronic disease areas, such as diabetes and autoimmune diseases. However, the fact that Lyndra failed to secure funding despite the positive Phase 3 data suggests that market skepticism remains, and the successful execution of partnership agreements will be a critical turning point for Nortiva's value realization.